Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02474368 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

A Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 1
Development phase
21
Enrollment target
1
Study location

NCT02474368 is a Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants, below the 51-participant average among 4 other Recurrent Head and Neck Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02474368, a Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

Conditions Studied

Recurrent Head and Neck Carcinoma Head and Neck Cancer Metastatic Head or Neck Cancer

Interventions

  • DRUG Cisplatin
  • RADIATION Intensity Modulated Radiation Therapy (IMRT)
  • RADIATION Stereotactic Body Radiotherapy (SBRT)

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2015-11
Est. Completion 2026-06
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02474368

The ClinicalTrials.gov registry entry for NCT02474368 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 4 other Recurrent Head and Neck Carcinoma trials with a reported enrollment target (59% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Head and Neck Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.

NCT02474368 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02474368 about?

NCT02474368 is a clinical study titled "Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck". This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of...

What is the current status of trial NCT02474368?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-11. Estimated completion is 2026-06.

What conditions does trial NCT02474368 study?

This clinical trial studies the following conditions: Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer.

What interventions are being tested in trial NCT02474368?

The interventions under investigation include: Cisplatin (DRUG), Intensity Modulated Radiation Therapy (IMRT) (RADIATION), Stereotactic Body Radiotherapy (SBRT) (RADIATION).

Who is sponsoring clinical trial NCT02474368?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02474368 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Head and Neck Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Head and Neck Carcinoma

All registered trials for this condition

Head and Neck Cancer Metastatic

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.